Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? comment

被引：5
作者：
Tarantino, Paolo [1 ,2 ]
Tolaney, Sara M. [3 ,4 ]
Harbeck, Nadia [5 ,6 ]
Cortes, Javier [7 ,8 ]
Curigliano, Giuseppe [1 ,2 ]
机构：
[1] European Inst Oncol IRCCS, Div New Drugs & Early Drug Dev, Via Ripamonti 435, Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
[5] LMU Univ Hosp, Breast Ctr, Dept Obstet & Gynecol, Munich, Germany
[6] Comprehens Canc Ctr CCCMunich, Munich, Germany
[7] Int Breast Canc Ctr IBCC, Grp Quironsalud, Barcelona, Spain
[8] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 32期
关键词：
FREE CHEMOTHERAPY REGIMENS; PLUS TRASTUZUMAB; CARDIAC SAFETY; PERTUZUMAB; PACLITAXEL; EFFICACY; COMBINATION; DOXORUBICIN; THERAPY;
D O I：
10.1200/JCO.21.01059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3541 / +
页数：6
相关论文
共 40 条
  • [1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
    Albain, K.
    Anderson, S.
    Arriagada, R.
    Barlow, W.
    Bergh, J.
    Bliss, J.
    Buyse, M.
    Cameron, D.
    Carrasco, E.
    Clarke, M.
    Correa, C.
    Coates, A.
    Collins, R.
    Costantino, J.
    Cutter, D.
    Cuzick, J.
    Darby, S.
    Davidson, N.
    Davies, C.
    Davies, K.
    Delmestri, A.
    Di Leo, A.
    Dowsett, M.
    Elphinstone, P.
    Evans, V.
    Ewertz, M.
    Gelber, R.
    Gettins, L.
    Geyer, C.
    Goldhirsch, A.
    Godwin, J.
    Gray, R.
    Gregory, C.
    Hayes, D.
    Hill, C.
    Ingle, J.
    Jakesz, R.
    James, S.
    Kaufmann, M.
    Kerr, A.
    MacKinnon, E.
    McGale, P.
    McHugh, T.
    Norton, L.
    Ohashi, Y.
    Paik, S.
    Pan, H. C.
    Perez, E.
    Peto, R.
    Piccart, M.
    [J]. LANCET, 2012, 379 (9814) : 432 - 444
  • [2] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
    Alberro, J. A.
    Ballester, B.
    Deulofeu, P.
    Fabregas, R.
    Fraile, M.
    Gubern, J. M.
    Janer, J.
    Moral, A.
    de Pablo, J. L.
    Penalva, G.
    Puig, P.
    Ramos, M.
    Rojo, R.
    Santesteban, P.
    Serra, C.
    Sola, M.
    Solarnau, L.
    Solsona, J.
    Veloso, E.
    Vidal, S.
    Abe, O.
    Abe, R.
    Enomoto, K.
    Kikuchi, K.
    Koyama, H.
    Masuda, H.
    Nomura, Y.
    Ohashi, Y.
    Sakai, K.
    Sugimachi, K.
    Toi, M.
    Tominaga, T.
    Uchino, J.
    Yoshida, M.
    Coles, C. E.
    Haybittle, J. L.
    Moebus, V.
    Leonard, C. F.
    Calais, G.
    Garaud, P.
    Collett, V.
    Davies, C.
    Delmestri, A.
    Sayer, J.
    Harvey, V. J.
    Holdaway, I. M.
    Kay, R. G.
    Mason, B. H.
    Forbe, J. F.
    Franci, P. A.
    [J]. LANCET ONCOLOGY, 2018, 19 (01) : 27 - 39
  • [3] Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
    Alizadeh, Darya
    Trad, Malika
    Hanke, Neale T.
    Larmonier, Claire B.
    Janikashvili, Nona
    Bonnotte, Bernard
    Katsanis, Emmanuel
    Larmonier, Nicolas
    [J]. CANCER RESEARCH, 2014, 74 (01) : 104 - 118
  • [4] [Anonymous], 2021, Breast cancer
  • [5] COMBINATION CHEMOTHERAPY AS AN ADJUVANT TREATMENT IN OPERABLE BREAST-CANCER
    BONADONNA, G
    BRUSAMOLINO, E
    VALAGUSSA, P
    ROSSI, A
    BRUGNATELLI, L
    BRAMBILLA, C
    DELENA, M
    TANCINI, G
    BAJETTA, E
    MUSUMECI, R
    VERONESI, U
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (08) : 405 - 410
  • [6] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
    Burstein, H. J.
    Curigliano, G.
    Loibl, S.
    Dubsky, P.
    Gnant, M.
    Poortmans, P.
    Colleoni, M.
    Denkert, C.
    Piccart-Gebhart, M.
    Regan, M.
    Senn, H. -J.
    Winer, E. P.
    Thurlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (10) : 1541 - 1557
  • [7] Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy The ACOSOG Z1041 (Alliance) Randomized Clinical Trial
    Buzdar, Aman U.
    Suman, Vera J.
    Meric-Bernstam, Funda
    Leitch, Ann Marilyn
    Ellis, Matthew J.
    Boughey, Judy C.
    Unzeitig, Gary W.
    Royce, Melanie E.
    Hunt, Kelly K.
    [J]. JAMA ONCOLOGY, 2019, 5 (01) : 45 - 50
  • [8] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Cardoso, F.
    Kyriakides, S.
    Ohno, S.
    Penault-Llorca, F.
    Poortmans, P.
    Rubio, I. T.
    Zackrisson, S.
    Senkus, E.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1194 - 1220
  • [9] Immunotherapy as a partner for HER2-directed therapies
    Clifton, Guy T.
    Peoples, George E.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 739 - 746
  • [10] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    Cortazar, Patricia
    Zhang, Lijun
    Untch, Michael
    Mehta, Keyur
    Costantino, Joseph P.
    Wolmark, Norman
    Bonnefoi, Herve
    Cameron, David
    Gianni, Luca
    Valagussa, Pinuccia
    Swain, Sandra M.
    Prowell, Tatiana
    Loibl, Sibylle
    Wickerham, D. Lawrence
    Bogaerts, Jan
    Baselga, Jose
    Perou, Charles
    Blumenthal, Gideon
    Blohmer, Jens
    Mamounas, Eleftherios P.
    Bergh, Jonas
    Semiglazov, Vladimir
    Justice, Robert
    Eidtmann, Holger
    Paik, Soonmyung
    Piccart, Martine
    Sridhara, Rajeshwari
    Fasching, Peter A.
    Slaets, Leen
    Tang, Shenghui
    Gerber, Bernd
    Geyer, Charles E., Jr.
    Pazdur, Richard
    Ditsch, Nina
    Rastogi, Priya
    Eiermann, Wolfgang
    von Minckwitz, Gunter
    [J]. LANCET, 2014, 384 (9938) : 164 - 172
1234